Pila Pharma AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PILA.ST research report →
Companypilapharma.com
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
- CEO
- Gustav Hanghoj Gram
- IPO
- 2021
- Employees
- 1
- HQ
- Malmö, SE
Price Chart
Valuation
- Market Cap
- $77.43M
- P/E
- -5.99
- P/S
- 85.61
- P/B
- 3.11
- EV/EBITDA
- -11.62
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -185.48%
- Op Margin
- -675.01%
- Net Margin
- -849.10%
- ROE
- -137.36%
- ROIC
- -41.30%
Growth & Income
- Revenue
- $1.13M · 45.42%
- Net Income
- $-16,863,000 · -50.01%
- EPS
- $-0.49 · -11.36%
- Op Income
- $-7,894,000
- FCF YoY
- -17.42%
Performance & Tape
- 52W High
- $3.93
- 52W Low
- $1.02
- 50D MA
- $1.64
- 200D MA
- $1.91
- Beta
- -0.32
- Avg Volume
- 114.56K
Get TickerSpark's AI analysis on PILA.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PILA.ST Coverage
We haven't published any research on PILA.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PILA.ST Report →